-
Company Insights
Innovation and Patenting activity of TP ICAP Group plc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of TP ICAP Group plc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nimacimab in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nimacimab in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nimacimab in Obesity Drug Details: Nimacimab (RYI-018) is under development for the treatment...
-
Company Profile
TP ICAP Group plc – Company Profile
TP ICAP Group plc (TP ICAP) is a global brokerage and information company. Its offerings comprise treasury, credit research, equities, alternative investments, energy and commodities, global currencies, tpMobile, and electronic markets platform. The company provides risk management services, daily activity summary, tpSEF information, tpMatch, and ad tpMatch inflation. The company operates through a hybrid business model where brokers offer business-critical intelligence to clients, supplemented by proprietary screens that provide historical data, analytics, and execution functionality. It offers proprietary over-the-counter pricing...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – nimacimab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry nimacimab Drug Details Nimacimab (RYI-018) is under development for the treatment of liver fibrosis...